Background Research suggests that sleep disturbance is common in psoriasis. While several sleep investigations have been conducted in psoriasis populations, many have methodological shortcomings, and no study has examined multiple dimensions of sleep-wake functioning. Moreover, research has yet to be performed comprehensively examining the range of physical and psychological factors that may affect sleep in people with psoriasis. Objectives To characterize sleep disturbance using validated measures and to identify physical and psychological predictors of sleep quality in people with psoriasis. Methods An online survey was conducted (186 respondents; mean age 39Á2 years) comprising validated measures assessing sleep [Pittsburgh Sleep; Quality Index (PSQI), Berlin Questionnaire, Pre-Sleep Arousal Scale]; chronotype (MorningnessEveningness Questionnaire); mood (Hospital Anxiety and Depression Scale); itch (5-D Itch Scale); and psoriasis severity (Simplified Psoriasis Index). Group comparisons and regression analyses were used to examine predictors of poor sleep. Results The mean PSQI score was 9Á2 AE 4Á3, with 76Á3% scoring above the threshold for poor sleep (≥ 6 on the PSQI) and 32Á5% scoring 'positive' for probable obstructive sleep apnoea (OSA). Poor sleep and high likelihood of OSA were associated with more severe psoriasis (P < 0Á05; g = 0Á07; g 2 = 0Á005). Cognitive arousal (b =
Psoriasis is a complex immune-mediated inflammatory disease primarily impacting on skin and affecting 2-3% of the population worldwide. 1 It has well-established associations with a number of other conditions, including cardiovascular disease (CVD), 2 inflammatory bowel disease, 3 psoriatic arthritis, 4 diabetes 5 and depression and anxiety. 6 The disease burden of psoriasis is greater than that of other chronic dermatological conditions 7 and equivalent to that experienced in populations with cancer, CVD and arthritis. 8 There is mounting interest in the relationship between sleep and psoriasis. A systematic review by our group showed that a high proportion (ranging from 0Á05% to 87Á5%) of individuals with psoriasis may experience sleep disturbances, 9 which are associated with itch, psychological distress (low mood and anxiety), pain and obstructive sleep apnoea (OSA). 9 However, the published literature demonstrates substantial variation in rates of disturbed sleep, and is limited by poor measurement of sleep, with many studies using unvalidated measures, in some cases just a single question. Indeed, lack of a comprehensive and valid examination of sleep, alongside incomplete data reporting, 9, 10 has hindered our understanding of sleep in psoriasis.
Sleep disturbance, including OSA, is associated with a range of adverse health outcomes including elevated risk for a range of physical diseases, several of which people with psoriasis are already more susceptible to (e.g. diabetes, 11 hypertension 12 and CVD). 13 Moreover, sleep disturbance increases the risk of psychological illness (e.g. depression 14 and anxiety) 15 and, over time, all-cause mortality. 16 Sleep is essential for metabolic 17 and immunological health, 18 while sleep disturbance may be proinflammatory and impact on psoriasis activity. [18] [19] [20] Indirect evidence supporting the impact of sleep on inflammation in psoriasis comes from a recent epidemiological study showing that the presence of a comorbid sleep disorder increases CVD risk by 25% in patients with psoriasis. 21 Additionally, relationships between circadian factors and psoriasis have been identified, with a longitudinal study reporting that regular night-shift work is associated with increased risk of developing psoriasis. 22 Circadian misalignment may disrupt normative metabolic and endocrine functioning, leading to adverse cardiometabolic complications, possibly through impairment of normal melatonin functioning. Melatonin is involved in sleep 23 and regulates inflammatory responses; 24 it may also lead to increased risk of psoriasis onset if chronically disrupted. 22 Based on the strong links identified between sleep, health and psoriasis, a multidimensional assessment of sleep in this population is warranted. While previous studies provide evidence of sleep disturbance in psoriasis, few studies have measured multiple domains of sleep disturbance in patients with psoriasis using validated tools. 9 A range of validated measures must be used to assess comprehensively the range of sleep dimensions, including sleep timing (i.e. chronotype), sleep quality, sleep continuity and sleep duration. Due to the limited appraisal of potential predictors of sleep quality in psoriasis we sought to examine the role of these in predicting poor sleep, focusing on variables associated with poor sleep in psoriasis including low mood, 14, 15, 25, 26 anxiety, 15, 27, 28 itch 29, 30 and, more generally, presleep arousal. [31] [32] [33] Our aims were as follows: firstly, to examine multiple dimensions of sleep-wake functioning in a representative community-based sample, and secondly, to identify the predictors of sleep disturbance, focusing on both physical and psychological variables known to interact with sleep in psoriasis.
Patients and methods

Design
We conducted a cross-sectional online survey using SelectSurvey.net (v4Á146Á001; ClassApps, Overland Park, KS, U.S.A.). This allowed an international sample to access the survey, and enabled participants to complete it in their own time.
Recruitment
Links for the survey were distributed via social media sites by the Psoriasis Association of Great Britain and Ireland, the National Psoriasis Foundation, the Canadian Psoriasis Association and The British Skin Foundation, and were posted on Facebook groups for members of the New Zealand Psoriasis Association along with other psoriasis support groups. Additional snowballing techniques were used: the survey link was distributed by the IMPACT research group's professional contacts (www.impac tpsoriasis.org.uk) and an existing psoriasis research database, and through posters placed in a U.K. university.
Participants
Inclusion criteria included: (i) a diagnosis of plaque psoriasis from a healthcare professional; (ii) age ≥ 18 years; and (iii) a good understanding of English. The survey was available to any individual with psoriasis regardless of whether or not they were experiencing sleep disturbance to ensure that variation in sleep quality was captured.
Procedure and analysis
Upon opening the survey link, participants were presented with an information sheet explaining the study's aims, content and research team contact details. Consent was provided online immediately preceding participation. Demographic questions and measures relating to sleep, mood, psoriasis and itch were presented for completion and included the following:
(i) The Pittsburgh Sleep Quality Index (PSQI). 34, 35 This assesses sleep quality and disturbance over 1 month. 40, 41 an established measure of depression and anxiety comprising 14 items, with seven relating to depression and seven relating to anxiety (each subscale scored 0-21). A higher score reflects greater distress. A cut-off score of 9 for each subscale indicates 'caseness' for probable clinical levels of distress.
(vi) The Simplified Psoriasis Index-Severity (SPI-S).
42 This is a self-assessment of psoriasis severity asking participants to rate the extent and plaque thickness, which are multiplied to obtain a severity score. Scores range from 0 to 50, with a higher score indicating more severe psoriasis. SPI-S scores < 5, < 10, > 18, > 19 and > 20 are equivalent to Psoriasis Area Severity Index scores < 5, < 10, > 15, > 18 and > 20, respectively.
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(vii) The 5-D Itch Scale, 44 a measure of the degree, duration, direction, disability and distribution of itch. It can be calculated to provide a global score of itch severity and impact. Scores range from 5 (no itch) to 25 (severe itch).
All questions on each page had to be completed in order to progress to the next page. Ethical approval for this study was obtained in June 2015 (reference 15/LO/1052).
Statistical analysis
Descriptive data were obtained for all variables. Normality was assessed, and due to positively skewed data, bootstrapping based on 5000 replications was applied to tests using psoriasis severity. Associations between questionnaire variables were tested using Pearson's product moment correlations, and point-biserial correlations when using OSA probability. Independent t-tests were used to compare psoriasis severity scores for normal (PSQI ≤ 5) and poor sleepers (PSQI ≥ 6) and to compare psoriasis severity scores between those with a high and low likelihood for OSA. One-way ANOVA was used to compare psoriasis severity scores for morning, intermediate and evening chronotype groups. Relative between-group effect sizes, expressed as eta-squared (g 2 ), were applied to estimate and compare the magnitude of observed effects. To examine which factors predicted poor sleep, multiple linear regression was performed for all variables that correlated with sleep (r ≥ 0Á4), 45 entered simultaneously. All analyses were conducted using SPSS (v22Á0; IBM, Armonk, NY, U.S.A.).
Results
Sample characteristics
In total, 186 people completed the survey between June 2015 and January 2016, providing complete data. Their mean age was 39 years (range 18-70), 140 (75Á3%) were female and they were from 15 countries (U.K., U.S.A., Canada, New Zealand, Australia, Ireland, Germany, Greece, Argentina, Egypt, India, France, Italy, Denmark, Puerto Rico). Partial data were obtained from 241 participants; however, many dropped out in the initial pages of the survey. Rather than substitute data for partially complete responses we chose to use complete data only. Psoriasis severity was predominantly mild, with a sample mean SPI-S score of 9Á6 AE 8Á6. The mean scores for the HADS depression and anxiety subscales were below the clinical thresholds, at 6Á5 AE 4Á2 and 8Á6 AE 4Á3, respectively. 41 
Sleep characteristics
Of 186 participants, 76Á3% (n = 142) were classified as poor sleepers, with the sample having a mean PSQI score of 9Á2 AE 4Á3. Sixty-one participants (32Á8%) had a high probability of OSA as determined by the Berlin Questionnaire. Consistently with elevated OSA probability, the mean body mass index for the sample was high at 30Á7 kg m À2 , with 26Á4% overweight (> 25 kg m À2 ) and 44Á8% obese (> 30 kg m À2 ).
Regarding presleep arousal, the mean score for the cognitive subscale was 21Á0 AE 7Á5, and 14Á5 AE 5Á9 for the somatic subscale. The mean MEQ score for the sample was 51Á4 AE 10Á0, with the majority possessing an intermediate chronotype (62Á9%), followed by morning (23Á1%), then evening (14Á0%). The participants' mean total sleep time was 371Á3 AE 89Á1 min, with 83Á3% classified as short sleepers (< 7 h), 14Á5% as normal sleepers (7-9 h) and 2Á2% as long sleepers (> 9 h). 46 The mean sleep efficiency for the sample was relatively poor at 75Á3 AE 17Á3%, with a mean sleep onset latency of 42Á4 AE 44Á0 min. Reported sleep problems related to poor subjective sleep quality (51%) two or more times per week, difficulties initiating sleep (52Á1%) two or more times per week and both difficulty with maintaining sleep and early awakening from sleep (79%) two or more times per week. Participants also reported difficulties sleeping due to being too hot and experiencing pain. Further details are provided in Table S1 (see Supporting Information). Descriptive data for all variables are presented in Table 1 . Comparisons of mean scores for normal and poor sleepers for each continuous measure can be seen in Figure 1 .
A significant difference was present in psoriasis severity scores (SPI-S) between normal sleepers (mean 6Á4 AE 5Á4) and poor sleepers [mean 10Á6 AE 9Á1, t(184) = 3Á73, P < 0Á001, g 2 = 0Á07], with poor sleepers having significantly higher psoriasis severity scores. Similarly, individuals with a high probability of OSA (mean 11Á6 AE 10Á3) had significantly higher psoriasis severity scores than those with a low probability [mean 8Á6 AE 7Á5, t(184) = 2Á03, P < 0Á05,
]. There were no significant differences in psoriasis severity scores between morning (mean 7Á8 AE 6Á9), intermediate (mean 10Á2 AE 8Á7) and evening (mean 9Á7 AE 10Á4) chronotype groups (P = 0Á28; g 2 = 0Á014).
Predictors of sleep quality
Next we evaluated the contribution of variables (age, sex, body mass index, psoriasis severity, mood, itch, presleep arousal, chronotype and OSA risk) to variation in sleep quality. Sleep quality was significantly positively correlated with psoriasis severity, anxiety, depression, itch, somatic arousal and cognitive arousal, and negatively correlated with chronotype ( Table 2 ). All variables except psoriasis severity, chronotype and OSA probability correlated with sleep quality at r ≥ 0Á4. Therefore, anxiety, depression, itch, and somatic and cognitive arousal were included in the subsequent regression analysis (Table 3) . Multiple regression analysis indicated that cognitive arousal (b = 0Á26, P < 0Á05), itch (b = 0Á26, P < 0Á001), depression (b = 0Á24, P = 0Á01) and somatic arousal (b = 0Á17, P < 0Á05) were independent predictors of sleep quality, together accounting for 43% of variance in PSQI scores.
Discussion
The aim of this study was to characterize sleep in psoriasis and to examine predictors of sleep quality. Our results show that poor sleep quality may be more common in psoriasis (76Á3%) than in the general population (estimated 30-50%). 47 Indeed, sleep quality and sleep efficiency were worse than previously reported in cohorts with psoriasis [48] [49] [50] or diabetes 51 and are equivalent to those seen in psoriatic arthritis. 52 Additionally, we observed a high probability of OSA in our sample (32Á8%), again at a rate higher than the prevalence in the general population (3-7%), 53 although somewhat lower than the rate of around 50% reported in other psoriasis samples.
54,55
Short sleep duration (< 7 h) was common in our sample, reported by the majority (83Á3%). Short sleep duration has well-established links with negative health consequences including obesity, 56 diabetes 57,58 and hypertension, 59 and thus may contribute to increased disease burden. Participants reported difficulties initiating and maintaining sleep, alongside early awakening with an inability to resume sleep; these are core features of insomnia. 60 Indeed, there was high presleep cognitive and somatic arousal in our sample, at least as high as in patients with clinical insomnia. 61 Presleep arousal is a known feature of insomnia, frequently precipitating and contributing to sleep difficulties 31, 62 and manifesting as cognitive (rumination, worry and negative emotion), 32 somatic (elevated sympathetic activity, metabolic rate and hypothalamicpituitary-adrenal axis activity) [63] [64] [65] and cortical (increased brain metabolism and high-frequency electroencephalogram activity) 66, 67 hyperarousal.
The elevated OSA probability present in our sample is consistent with the high mean body mass index score found, with obesity being a known risk factor for OSA 68 and common in people with psoriasis. 69 It is likely that lifestyle factors (e.g. obesity and physical inactivity) are involved and may contribute to this elevated risk. 55 Nevertheless, it has been proposed that psoriasis and OSA are linked bidirectionally via inflammatory pathways, with both disorders demonstrating increased concentrations of interleukin (IL)-17, IL-6 and tumour necrosis factor-a. [70] [71] [72] [73] While the precise mechanisms linking OSA and psoriasis remain unclear, there is some evidence suggesting that links between lifestyle factors and CVD/ hypertension may underlie this elevated risk. 74 It is worth mentioning that the OSA estimates in this study are lower than reported elsewhere 9 and may be due to the use of a selfreported measure (Berlin Questionnaire) rather than polysomnography to assess OSA. However, the Berlin Questionnaire has proven validity, and a moderate-to-strong positive predictive value, ranging from 0Á72 75 to 0Á89. 36 Given that OSA is a known risk factor for CVD, 76 ischaemic stroke, 77 road traffic accidents 78 and hypertension, 79 we suggest that sleep disordered breathing is queried in patients with psoriasis to facilitate appropriate diagnosis and treatment. Cognitive arousal, itch, depression and somatic arousal were identified as key predictors of sleep quality. Elevated arousal in the presleep period is associated with sleep difficulties in insomniacs and healthy individuals, contributing to increased sleep onset latency, reduced sleep efficiency and total sleep time and sleep-state misperception. [31] [32] [33] Although this is speculative, a number of factors may contribute to elevated arousal in psoriasis, including disease-related rumination and worry, and monitoring of somatic symptoms, such as itch. Further arousal may stem from disrupted emotional regulation, resulting in negatively toned emotional activity, with sleep disturbances known to modulate emotional responses. 80, 81 It is likely that anxiety did not emerge as a significant predictor due to the probable shared variance between the HADSanxiety and Pre-Sleep Arousal Scale-cognitive subscales. The content of this elevated arousal in the presleep period could be investigated further, examining psoriasis-specific factors. Itch and associated scratching have been reported as disrupting sleep in psoriasis and other pruritic conditions, with scratching occurring throughout the sleep period. [82] [83] [84] [85] Evidence suggests that conditioned scratching activity can occur during sleep, with nocturnal scratching reported as a distinct parasomnia in a number of cases. 86 Moreover, itch has strong links with mood, 87 with depression amplifying itch perception. 88 In addition, wellestablished links between depression and sleep exist, with low mood and insomnia interacting bidirectionally, 14, 89 suggesting the existence of shared aetiology. 14, 26 Future research could focus on prospectively examining the causal direction between these predictors and poor sleep, with the aim of identifying possible mediating pathways. A key strength of this study is that it provides a multidimensional assessment of sleep using validated measures in an international sample. Despite this, there are limitations that must be considered. Firstly, our study may have been subject to selection bias, with people who experience sleep disruption having a greater motivation to participate. We attempted to minimize this by inviting all individuals with psoriasis regardless of sleep status to participate. Moreover, although the majority of our sample had mild psoriasis, the magnitude of sleep disturbance and high levels of presleep arousal suggest that poor sleep is a prevalent issue in this group. We believe the distribution of psoriasis severity observed in this study is sufficiently similar to that found elsewhere. 90 However, it is unclear why there was a predominance of women participating in the study. It could be speculated that this is due to a higher prevalence of insomnia, and thus may be the result of selection bias. 91 Indeed, evidence suggests that women are more likely to respond to survey research, with similar sex distributions to those encountered here observed in other sleep-related survey studies. 92, 93 It is also unclear why we obtained a low participation rate relative to the recruitment efforts. Over 11 800 individuals engaged with the survey link; however, 11 471 did not continue past the information sheet. We are unsure why this is; however, a contributing factor may have been the number of questions included. Another significant limitation of this study is the lack of a control group, limiting our ability to generalize the prevalence of sleep disturbance found in this study to the psoriasis population as a whole. A further limitation stems from the use of subjective sleep measures, which, while valid, were retrospective in nature and thus may be subject to recall biases, which is a limitation of cross-sectional research. Additionally, we did not examine other sleep disorders such as sleep-related movement disorders, circadian rhythm disorders, parasomnias or excessive daytime sleepiness, and thus hidden sleep pathology may not have been detected. Finally, with the study being cross-sectional we are limited in our ability to explore the causal ordering of variable relationships.
In summary, our findings suggest that sleep disturbance is more common than previously thought in psoriasis, and that it is associated with a range of psychological and physical factors. While a handful of studies have shown improvements in sleep in psoriasis following administration of biological medication, 94, 95 this should be combined with psychological therapies specifically targeting the modifiable factors identified here, including itch, negative mood and presleep arousal. Therapeutic focus on these variables may lead to improvements in sleep in people with psoriasis.
